Next Article in Journal
Identification, Characterization, and Immobilization of an Organic Solvent-Stable Alkaline Hydrolase (PA27) from Pseudomonas aeruginosa MH38
Previous Article in Journal
Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

CARI III Inhibits Tumor Growth in a Melanoma-Bearing Mouse Model through Induction of G0/G1 Cell Cycle Arrest

Department of Food Science and Biotechnology, College of BioNano Technology Gachon University, Sungnam Gyeonggi-do 461-701, Korea
Molecules 2014, 19(9), 14383-14395; https://doi.org/10.3390/molecules190914383
Submission received: 23 June 2014 / Revised: 23 July 2014 / Accepted: 25 July 2014 / Published: 12 September 2014
(This article belongs to the Section Medicinal Chemistry)

Abstract

Mushroom-derived natural products have been used to prevent or treat cancer for millennia. In this study, we evaluated the anticancer effects of CARI (Cell Activation Research Institute) III, which consists of a blend of mushroom mycelia from Phellinus linteus grown on germinated brown rice, Inonotus obliquus grown on germinated brown rice, Antrodia camphorata grown on germinated brown rice and Ganoderma lucidum. Here, we showed that CARI III exerted anti-cancer activity, which is comparable to Dox against melanoma in vivo. B16F10 cells were intraperitoneally injected into C57BL6 mice to develop solid intra-abdominal tumors. Three hundred milligrams of the CARI III/kg/day p.o. regimen reduced tumor weight, comparable to the doxorubicin (Dox)-treated group. An increase in life span (ILS% = 50.88%) was observed in the CARI III-administered group, compared to the tumor control group. CARI III demonstrates anti-proliferative activity against B16F10 melanoma cells through inducing G0/G1 cell cycle arrest. CARI III inhibits the expression of cyclin D1, CDK4 and CDK2 and induces p21. Therefore, CARI III could be a potential chemopreventive supplement to melanoma patients.
Keywords: mushroom mixture; CARI III; melanoma; G0/G1 cell cycle arrest; anti-cancer; cyclin D1; CDK4; CDK2 mushroom mixture; CARI III; melanoma; G0/G1 cell cycle arrest; anti-cancer; cyclin D1; CDK4; CDK2

Share and Cite

MDPI and ACS Style

Park, H.-J. CARI III Inhibits Tumor Growth in a Melanoma-Bearing Mouse Model through Induction of G0/G1 Cell Cycle Arrest. Molecules 2014, 19, 14383-14395. https://doi.org/10.3390/molecules190914383

AMA Style

Park H-J. CARI III Inhibits Tumor Growth in a Melanoma-Bearing Mouse Model through Induction of G0/G1 Cell Cycle Arrest. Molecules. 2014; 19(9):14383-14395. https://doi.org/10.3390/molecules190914383

Chicago/Turabian Style

Park, Hye-Jin. 2014. "CARI III Inhibits Tumor Growth in a Melanoma-Bearing Mouse Model through Induction of G0/G1 Cell Cycle Arrest" Molecules 19, no. 9: 14383-14395. https://doi.org/10.3390/molecules190914383

APA Style

Park, H.-J. (2014). CARI III Inhibits Tumor Growth in a Melanoma-Bearing Mouse Model through Induction of G0/G1 Cell Cycle Arrest. Molecules, 19(9), 14383-14395. https://doi.org/10.3390/molecules190914383

Article Metrics

Back to TopTop